BioSpace News Archive

Vifor Pharma today announced that the first patient has been enrolled in a double-blind, randomized phase-IIa clinical trial evaluating the safety, efficacy and tolerability of vamifeport in adult patients with sickle cell disease.

Johnson & Johnson will host a conference call for investors at 8:30 a.m. on Tuesday, January 25th to review fourth-quarter results.

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, presented an update from its Phase II SUMMIT trial at the ongoing 2021 San Antonio Breast Cancer Symposium (SABCS) Annual Meeting.

Abbott announced that its Board of Directors has elected Chief Executive Officer Robert B. Ford as Chairman of the Board.

Increasing funding from public and private sector bodies for developing new products and support for promoting live cell encapsulation systems is a key factor fueling growth of the live cell encapsulation market.

According to Emergen Research, the global CRISPR/CAS 9 technology market size was USD 1,404.6 Million in 2020 and is expected to reach USD 6,221 Million in 2028 and register a revenue CAGR of 20.4% during the forecast period, 2021-2028.

Sumitovant Biopharma, Inc. today announced that its portfolio of four wholly-owned subsidiary companies (Urovant, Enzyvant, Altavant and Spirovant) and Myovant (NYSE: MYOV), a publicly listed company that is majority-owned by Sumitovant, achieved significant clinical, regulatory and commercial milestones during the company’s second quarter of fiscal year 2021 ending in October.

Duchenne muscular dystrophy is a progressive genetic disorder causing severe disability and early death.

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company’s common stock to $0.40 for the first-quarter 2022 dividend, payable March 4, 2022, to holders of the Common Stock of record at the close of business on January 28, 2022.

Abbott (NYSE: ABT) today announced that its board of directors has increased the company’s quarterly common dividend, marking the company’s 50th consecutive year of dividend growth.